Association between serum free fatty acid levels and possible related factors in patients with type 2 diabetes mellitus and acute myocardial infarction

Zhi-Hua Lv†, Pei Ma†, Wan Luo, Hui Xiong, Lu Han, Si-Wei Li, Xin Zhou* and Jian-Cheng Tu*

Abstract

Background: Free fatty acids (FFAs) play importance roles in the development of diabetes and cardiovascular diseases. We measured serum FFA levels from type 2 diabetes mellitus (T2DM) and acute myocardial infarction (AMI) patients and assay the correlation between serum FFA levels and related factors. The present study was undertaken to investigate a possible relation between the changes in serum free fatty acid concentration with acute myocardial infarction and type 2 diabetes mellitus.

Methods: The study population consisted of 540 healthy individuals and 103 patients with T2DM, 59 patients with AMI and 21 volunteers. Serum FFAs were measured with high pressure liquid chromatography. Blood urea nitrogen and uric acid were measured in clinical laboratory, as were glycemic, lipid and blood routine parameters. We selected 242 individuals with age over 60 years, 143 healthy individuals and 52 patients with T2DM, 47 patients with AMI were incorporated into three groups as control group, T2DM group and AMI group. Associations were analyzed with stepwise regression analysis with adjusted for age, sex, body mass index.

Results: Serum FFA levels were significantly higher in the age over 60 years individuals compared to 20 ~ 50 years (logFFA μmmol/L: 2.60 ± 0.16 vs. 2.73 ± 0.18, P < .001) in the healthy group. We found lower FFA levels in the AMI compared to the T2DM and control group (2.64 ± 0.22 vs. 2.72 ± 0.13 & 2.72 ± 0.16, respectively, P < .05 & P < 0.01) in the age over 60, fasting blood glucose level higher in the AMI and T2DM (5.78 ± 1.32 & 7.75 ± 2.93 mmol/L vs. 4.90 ± 0.47 mmol/L, P < .01 & P < .001) compared with the normal group, HDL level (1.01 ± 0.22 & 0.98 ± 0.18 mmol/L vs. 1.30 ± 0.22 mmol/L, P < .001 & P < .001). With stepwise regression analysis, the serum FFA levels was positively associated with the HDL in the control group (YlogFFA = 2.32 + 0.33XHDL, R = 0.26, P < .01) and T2DM (YlogFFA = 2.46 + 0.27XHDL, R = 0.36, P < .05), AST in AMI (YlogFFA = 2.24 + 0.15XAST, R = 0.49, P < .01).

Conclusions: Compared to control group, serum FFA levels were decreased only in AMI group, while HDL level was increased in both AMI and T2DM group. The serum FFA levels were positive association with the HDL level in both T2DM and control group, FFA levels were positive association with AST in AMI.

Keywords: Acute myocardial infarction (AMI), Type 2 diabetes mellitus (T2DM), Free fatty acid (FFA), High density lipoprotein cholesterol (HDL-c), Aspartate aminotransferase (AST)
Background
More than 347 million patients had diabetes around the world in 2008 [1], the World Health Organization projected that diabetes was likely to become the 7th leading cause of death in 2030 [2]. Diabetes increases the risk of cardiovascular disease and stroke, about 50% of people with diabetes die of cardiovascular disease [3]. Diabetes-associated atherosclerosis has been estimated to affect 5-8% of the general population and was by itself a major cause of death among diabetic patients with accounting for 50% of mortality [4]. Dyslipidemia contributes to diabetes-associated atherosclerosis and even to insulin resistance [5], and strong evidence supports the role of free fatty acids (FFAs) in promoting insulin resistance [6]. Insulin resistance increases atherogenesis and induces proinflammatory activities on vascular. Hyperglycemia caused feedback loop, increasing lipolysis and leading to a chronic exposure to the FFAs [6-8].

Cardiovascular diseases (CVDs) have emerged as the dominant contributor to total global, and the total number of CVDs deaths increased from 14.4 million in 1990 to 17 million in 2008. More than seven million patients are reportedly diagnosed with AMI each year, 90% of myocardial infarctions are attributable to modifiable risk factors as smoking, dyslipidemia, hypertension and diabetes [9]. Some studies have recently reported that STEMI patients with high glucose are related to adverse impact on survival, and the plasma FFAs concentration has been associated with lip toxicity, apoptosis, and risk of diabetes mellitus and coronary heart disease [10].

Circulating FFAs are albumin-bound lipid molecules principally derived from adipose tissue lipolysis [11]. The FFAs is a major fuel in mammals besides glucose. It is established that the excess supply of FFAs could suppress food intake and reduce hepatic glucose output. An overabundance of FFAs, due to exogenous lipid infusions or obesity, can lead to insulin resistance, vascular dysfunction, and myocardial dysfunction. Additional studies are needed to explore biological mechanisms that FFAs may influence the happen of AMI.

Methods
Subjects
This study was carried out at the Zhongnan Hospital of Wuhan University and Renmin Hospital of Wuhan University. The research protocol was approved by the Medical Ethics Committee of the Zhongnan Hospital of Wuhan University. All individuals provided informed consent with verbally or in writing. The normal group population was selected from those who underwent a comprehensive health examination at Zhongnan Hospital of Wuhan University, Renmin Hospital of Wuhan University. The study subjects included 103 T2DM and 59 AMI patients who had been hospitalized at two departments: Department of endocrinology and cardiovascular medicine in Zhongnan Hospital of Wuhan University. The 21 volunteers were graduate students from the Center for Gene Diagnosis of Zhongnan Hospital of Wuhan University. The health examination individuals were selected for participation based on the following criteria: liver, kidney function and blood test were in the normal range for the most parameters, and without other systemic disease history.

Type 2 diabetes was defined according to the American Diabetes Association (ADA) [12]. Any one of the following criteria meets the diagnosis for T2DM (In the absence of unequivocal hyperglycemia, criteria 1–3 should be confirmed by repeat testing): (1) HbA1c ≥6.5%. (2) FPG ≥7.0 mmol/l. (3) Two-hour plasma glucose ≥11.1 mmol/l during an OGTT. (4) In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥11.1 mmol/l. Patients were excluded for the following reasons: (1) Patients who were diagnosed with type 1 diabetes mellitus (2) Patients who were complicated with cardiovascular disease, viral hepatitis, tumor, autoimmune disease, serious liver or kidney dysfunction (3) patients who use lipid-lowering drugs (e.g. Lipitor and Zocor, etc, which are in a class of drugs known as statins).

AMI was defined according ESC/ACCF/AHA/WHF [13,14]. Detection of a rise of cardiac troponin (cTn) with at least one above the 99th percentile upper reference limit (cTnT ≥0.01 ng/L) and with at least one of the following: (1) Symptoms of ischaemia: chest pain lasting 30min or longer. (2) New or presumed new significant ST-segment-T wave (ST-T) changes or new left bundle branch block (LBBB). (3) Development of pathological Q waves in the ECG. (4) Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality. (5) Identification of an intracoronary thrombus by angiography or autopsy. Patients were excluded for the following reasons: (1) Previous myocardial infarction. (2) Patients who were complicated with diabetes mellitus, viral hepatitis, tumor, autoimmune disease, serious liver or kidney dysfunction. (3) Patients who used lipid-lowering drugs (e.g. Lipitor and Zocor, etc. which are in a class of drugs known as statins).

Study population
Height (cm) and weight (kg) were measured in the standing position when health examination or admission. Venous blood samples were collected after overnight fasting for T2DM patients, healthy examination individuals and volunteers. Venous blood samples were collected for AMI patients within 4 hours of admission. Serum samples were prepared by centrifugation at 2000 rpm for 10 min at 4°C. Blood routine parameters were measured using the automatic hematology analyzer (Beckman-CoulterLH750, USA). The inter-assay coefficients of variation (CV%) amounts to 3.6% and 2.9% in the higher normal and lower normal range.
respectively. Fasting serum glucose (GLU), total cholesterol (TC), triglyceride (TG) and high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), Serum aminotransferase (ALT) and aspartate aminotransferase (AST), serum urea nitrogen (BUN), uric acid concentrations were measured using the automated chemistry analyzer (Olympus AU5400 biochemistry analyzer, Japan). The inter-assay coefficients of variation (CV%) amounts to 3.9% and 2.7% in the higher normal and lower normal range respectively. Serum samples for FFAs assays were stored at −80°C until analysis. Serum FFA levels were measured with high pressure liquid chromatography (HPLC) within one hour after rehydration.

Statistical analysis
SPSS 13.0 software was used for statistical analysis. Categorical variables were expressed as proportions and compared between groups using the X² test. Continuous data are expressed as mean ± SD for normally distributed variables or median (inter quartile range) for others. The paired t-test was used to compare continuous variables. Unavailable relationships were calculated with Pearson correlation coefficients. Comparison of the groups by ANOVA was followed by SNK-q test to determine differences between individual groups. Multivariable stepwise regression analyses were performed to determine the independent correlation factors to FFA. Because of skewed distribution, the values of FFA were transformed in logarithmically for analysis. The level of significance was set at P < .05.

Results
The stability of FFAs
A total of 21 volunteer subjects were enrolled in this study. Mean age was 26.7 ± 2.3 years, and 33% were men. The serum sample was stored at room temperature (1 h, 4 h, 8 h, 24 h) and at 4°C 4 h, and plasma sample at room temperature 1 h and at 4°C 4 h. There was no significant difference in serum FFA levels between the room temperature 1 h and 4°C 4 h (407.3 ± 148.4 mmol/L vs. 406.2 ± 148.1 mmol/L, P = 0.19). The FFA levels began to increase in those groups under room temperature (4 h: 416.9 ± 149.2 mmol/L; 8 h: 419.5 ± 149.2 mmol/L; 24 h: 513.8 ± 151.2 mmol/L; P < .001) compared to room temperature 1 h (407.3 ± 148.4 mmol/L) (Figure 1A). Plasma FFA levels were significant lower compared to the serum levels (room temperature 1 h: 351.3 ± 137.9 mmol/L vs. 407.3 ± 148.4 mmol/L; P < .001). The scatter plot also showed an elevated of FFA levels with the storing time lasted (R² = 0.957, P < .001, Figure 1B).

The FFA levels in different age and gender.
We divided 540 healthy individuals into six sub-groups (Figure 2). There was a significant difference among the six sub-groups after adjusted for sex and BMI, the FFA levels had a trend of increasing with the age, but not enough to achieved statistically significant among the age among 20 ~ 50 years and 60 ~ years. We found no difference between sexes (Table 1).

Baseline characteristics
Baseline characteristics were shown in Table 2. A total of 242 eligible consecutive individuals were included which age was over 60 years between June 2013 to October 2013. There were 143, 52 and 47 subjects in the control group, T2DM and AMI, respectively. All data were in a normal distribution exclude ALT, AST and FFAs.

Associations of FFAs with other conceivable factors
In this part, 242 subjects were chosen according to age greater than or equal to 60 (129/242 were men; 71.0 ± 6.8 years). There were 143, 52 and 47 subjects in the control group, T2DM and AMI, respectively. We compared the three groups with one-way ANOVA (Figure 3). Serum

![Figure 1](#) The change of FFA levels with different storing temperature and time. The histogram showed FFA levels (A) 4 represents stored at 4°C 4 h, others stored at room temperature. Scatter plots show relationships of storing time (h) and serum FFA (B). ***P < .001, paired t-test: compared to room temperature 1 h. ###P < .001, paired t-test: compared to 4°C 4 h. The dotted line was a virtual-line.
levels of the triglyceride (TG) and glucose (GLU) were significantly higher in individuals with T2DM and AMI compared to control, as TG (2.02 ± 1.29 mmol/L vs. 1.12 ± 0.33 mmol/L, P < .001) and glucose (7.75 ± 2.93 mmol/L vs. 4.90 ± 0.49 mmol/L, P < .001) (Figure 3A) and (Figure 3B). The HDL levels were lower in T2DM (0.98 ± 0.18 mmol/L, P < .001) and AMI (1.01 ± 0.22 mmol/L, P < .001) compared to control group (1.30 ± 0.22 mmol/L) (Figure 3B). And serum FFAs and AST obtained significant difference in AMI compared to T2DM or control (P < .001) (Figure 3E and F).

The participants were divided the participants into four groups based on the age as shown in Table 3. Stepwise multivariable regression models were used to find the association of FFA with each of the other factors with adjusted sex and BMI. Those factors ALT, AST, TC, TG, HDL, LDL, BUN, TP and fasting glucose were incorporated into the regression models.

For stepwise multivariable regression analysis, we selected the variables that were allowed to enter the model in advance. HDL and TG were associated with The FFAs in the control group (20 ~ 50 years) (R = 0.28, P < .001) and were allowed to enter the multivariable model, so was HDL was associated with FFAs in the control group (≥60 years) (R = 0.26, P < .01) and T2DM (≥60 years) (R = 0.36, P < .05), AST was associated with The FFAs in the AMI (≥60 years) (R = 0.487, P < .01).

**Discussion**

The current study demonstrates that nearly two-thirds of patients with cardiovascular disease suffer from abnormal glucose metabolism [15,16], and type 2 diabetes is associated with a twofold to fourfold increased risk of both coronary heart disease and stroke [17]. Cardiovascular disease was also the most common underlying cause of death in type 2 diabetes mellitus accounting for 52% [3].

In this study, the FFA levels had a trend of increasing with age, and no significant difference between sexes. Preliminary experiments show the FFA levels were instability in room temperature, and the difference between serum and plasma sample was also found. Also, the detection of FFAs is limited by the significant intra-individual range of variation, which can be strongly influenced by food intake and stress situations [18]. All individuals were included in the analysis of the age greater than or equal to 60. In stepwise multivariable regression, the FFAs were positive correlated with HDL in the health examination individuals or T2DM, however, no similar correlation in the AMI. And lower FFA was strongly associated with AST in the AMI.

FFAs serve as physiologically important energy substrates and their release from the adipose tissue by lipolysis is regulated according to the energy demands of the body. FFA elevations are both a risk factor of cardiovascular disease and are associated with metabolic, atherosclerosis, inflammation, insulin resistance and hyperlipidemia [19-23]. The 70% of energy was generated through β-oxidation of fatty acids and 30% through oxidation of ketone bodies and pyruvate in the cardiomyocytes [24,25]. A raised concentration of FFAs with subsequent increased β-oxidation in the cardiomyocytes can be harmful for the heart in various ways. Furthermore, increased FFAs can lead to damage to the plasma membrane and disturbances of the ion channels of the cardiomyocytes [25]. The fatty acid levels has been described an increase in myocardial infarction [26], however, we found the free fatty acid levels has a slight decrease in the early period of acute myocardial infarction, it may play an important role in the early stage of a first-time AMI.

The ratio of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol (LDL-c/HDL-c) is a reliable predictor of cardiovascular risk. Low HDL-C levels
Table 2 Baseline characteristics

|                      | Control group | T2DM          | AMI          |
|----------------------|---------------|---------------|--------------|
| Age (y)              | 71.0 ± 6.6    | 70.9 ± 7.3    | 71.3 ± 7.0   |
| Males, n (%)         | 81 (56.6%)    | 24 (46.2%)    | 24 (51.1%)   |
| BMI (kg/m2)          | 22.5 ± 2.6    | 23.5 ± 2.3**  | 22.3 ± 3.0   |
| Hypertension, n (%)  | 15 (10.6%)    | 9 (17.0%)     | 22 (46.8%)   |
| ALT (U/L), M (P25,P75)| 20 (17.25) | 23 (19.29)**  | 23 (19.31)** |
| AST (U/L), M (P25,P75)| 25 (22.28) | 23 (18.29) ** | 25 (21.30)   |
| Total Cholesterol (mmol/L) | 4.31 ± 0.59 | 4.59 ± 1.03* | 4.40 ± 0.90  |
| Triglycerides (mmol/L) | 1.12 ± 0.33  | 2.02 ± 1.29***| 1.63 ± 0.88**|
| HDL-cholesterol (mmol/L) | 1.30 ± 0.22  | 0.96 ± 0.18***| 1.00 ± 0.22**|
| LDL-cholesterol (mmol/L) | 2.35 ± 0.46  | 2.37 ± 0.77   | 2.25 ± 0.75  |
| Glucose (mmol/l)     | 4.90 ± 0.49   | 7.75 ± 2.95***| 5.78 ± 1.32**|
| BUN (mmol/l)         | 5.50 ± 1.28   | 5.78 ± 3.13   | 6.22 ± 2.82* |
| Uric acid (mmol/L)   | 281.3 ± 68.2  | 316.2 ± 96.9* | 366.3 ± 171.7##
| HCT                  | 41.6 ± 3.6    | 38.5 ± 5.2*** | 38.8 ± 4.9###|
| WBC (10*9/L)         | 6.15 ± 1.60   | 7.30 ± 3.78** | 7.12 ± 2.41* |
| Platelet (10*9/L)    | 178.7 ± 49.0  | 180.8 ± 63.0  | 182.0 ± 74.0 |
| Total Protein (g/L)  | 71.1 ± 6.0    | 67.4 ± 6.0*   | 66.5 ± 6.6## |
| FFAs (mmol/L)        | 551.6 (403.0,679.7) | 536.5 (412.6,666.3)** | 441.0 (298.5,625.0) |

Data are presented as mean ± SD, in a normal distribution of data, or as median (inter quartile range), in a skewed distribution of data.

*P < .05, **P < .01, ***P < .001 for the T2DM group vs. the control group.

#P <0.5, ##P < .01, ###P < .001 for the AMI group vs. the control group.

Figure 3 The description of six mainly levels in T2DM, AMI and control group. The histogram showed six mainly levels [TG (A), HDL (B), LDL (C), GLU (D), AST (E), FFAs (F)]. Data are mean ± SD. *P < .05, **P < .01, ***P < .001; Three groups: Control (n = 143), T2DM (n = 52), AMI (n = 47).
in patients with coronary artery disease are associated with a high risk for cardiovascular events [27]. LDL-c and non-HDL-c are likely to be the predictors of cardiovascular risk and as targets for treatment [28,29].

The liver transaminases, especially aspartate transaminase (AST), were first found their use in myocardial injury and necrosis in 1954 [30]. A total of 1783 patients were studied in 85.6% in acute myocardial infarction, CK-MB was associated with AST (r = 0.727), and independently associated with mortality and clinical outcomes [31]. FFAs may serve as physiologically important energy in AMI patients, and play as protective factors during the acute attack period of the AMI.

Conclusions

In conclusion, we found lower serum FFA levels in AMI during the acute attack period compared to the other two groups, independent of age, sex, BMI, the serum HDL levels were lower in both AMI and T2DM compared to control group, and AST levels were higher in AMI compared to control group. With stepwise multivariable regression analysis: the HDL was associated with the FFAs in control group and T2DM patients, but the AST was associated with the FFAs in the AMI, the FFAs possibly play importance roles in the AMI.

Abbreviations

FFA: Free fatty acid; T2DM: Type 2 diabetes mellitus; AMI: Acute myocardial infarction; BMI: Body mass index; HPLC: High pressure liquid chromatography; ALT: Serum aminotransferase; AST: Aspartate Aminotransferase; HDL-c: High-density lipoprotein cholesterol; LDL-c: Low-density lipoprotein cholesterol; TC: Total cholesterol; TG: Triglyceride; GLU: Fasting serum glucose; BUN: Serum urea nitrogen; WBC: White blood cell.

Competing interests

The authors declare that they have no competing interests.

Table 3 Stepwise multivariable regression model of the serum FFA levels

|          | Males, n (%) | Age (y) | Log (FFA) | R     | P-value |
|----------|--------------|---------|-----------|-------|---------|
| Control  | (20 ~ 50 years) | 145 (48.7%) | 39.3 ± 8.6 | 2.61 ± 0.16 | |
| HDL + TG |              |          |           | 0.28  | P < .001 |
| Control  | (≥60 years)   | 81 (56.6%) | 71.0 ± 6.6 | 2.72 ± 0.16 | |
| HDL      |              |          |           | 0.26  | P = 0.002 |
| T2DM     | (≥60 years)   | 24 (46.2%) | 70.9 ± 7.3 | 2.72 ± 0.13 | |
| HDL      |              |          |           | 0.36  | P = 0.01  |
| AMI      | (≥60 years)   | 24 (51.1%) | 71.3 ± 7.0 | 2.64 ± 0.22 | |
| AST      |              |          |           | 0.49  | P = 0.005 |

Authors’ contributions

LZH and MP participated in the design of the study, acquired and analyzed data, and wrote the manuscript. ZX and TJC conceived study, analyzed data, and helped draft the manuscript. HL, LSW, XH and LW acquired and researched data. All authors read and approved the final manuscript.

Acknowledgments

This work was supported by the Special Health Standards Infrastructure Program [grant number 20120094] funded by the Ministry of Science and Technology of China and Wuhan Project of Scientific and Technical Supporting Program [grant number 20120523]. We would like to conclude this article by expressing our gratitude to the Department of Medical Examination Center, for their cooperation with us and submission of valuable data. We thank all members of the Center for Gene Diagnosis, Zhongnan Hospital of Wuhan University. ZPA, PhD is acknowledged for data collection. Laboratory of Clinical Chemistry, Wuhan University, performed the serum assays.

Received: 24 January 2014 Accepted: 27 October 2014 Published: 14 November 2014

References

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, Lin JK, Farzadfar F, Khang YH, Stevens GA, Rao M, Ali MK, Riley LM, Robinson CA, Ezzati M, Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose): National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011, 371(9678):31–40.

2. Carley AN, Kleinfeld AM: Fatty acid (FFA) transport in cardiomyocytes revealed by imaging unbound FFA is mediated by an FFA pump modulated by the CD36 protein. J Biol Chem 2011, 286(8):4989–4997.

3. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Krum H: Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001, 44(Suppl 2):S14–S21.

4. Mas S, Martinez-Pinna R, Martin-Ventura JL, Perez R, Gomez-Garre D, Ortiz A, Fernandez-Cruz A, Vivanco F, Egido J: Local non-esterified fatty acids correlate with inflammation in atheroma plaques of patients with type 2 diabetes. Diabetes 2010, 59(5):1292–1301.

5. Holland WL, Knotts TA, Chavez JA, Wang LP, Hoenl KL, Summers SA: Lipid mediators of insulin resistance. Nutr Rev 2007, 65(6 Pt 2):S39–S46.

6. Montecucco F, Steffens S, Mach F: Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability. Mediators Inflamm 2008, 2008:7623.

7. Reiz-Madsen C, King GL: Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol 2008, 28(3):487–496.

8. Wilding JP: The importance of free fatty acids in the development of Type 2 diabetes. Diabet Med 2007, 24(9):934–945.

9. White HD, Chew DP: Acute myocardial infarction. Lancet 2008, 372(9638):570–584.

10. Djousse L, Benkeser D, Arnold A, Kizer JR, Ziemian SJ, Lemaître RN, Tracy RP, Goldtiener JS, Mozaffarian D, Siscovick DS, Mukamal KJ, KJ JH: Plasma free fatty acids and risk of heart failure: the Cardiovascular Health Study. Circ Heart Fail 2013, 6(5):964–969.

11. Wang S, Soni KG, Semache M, Casavant S, Fortier M, Pan L, Mitchell GA: Lipolysis and the integrated physiology of lipid energy metabolism. Mol Genet Metab 2008, 95(3):117–126.

12. American Diabetes Association: Standards of medical care in diabetes–2010. Diabetes Care 2010, 33(Suppl 1):S11–S61.

13. O’Gara PT, Kushner FG, Ascheim DD, Casey DJ, Chang MK, de Lemos JA, Ettinger SM, Fang JC, Fein unbelievably difficult to read.

Lancet 2008, 372(9638):570–584.

10. Djousse L, Benkeser D, Arnold A, Kizer JR, Ziemian SJ, Lemaître RN, Tracy RP, Goldtiener JS, Mozaffarian D, Siscovick DS, Mukamal KJ, KJ JH: Plasma free fatty acids and risk of heart failure: the Cardiovascular Health Study. Circ Heart Fail 2013, 6(5):964–969.

11. Wang S, Soni KG, Semache M, Casavant S, Fortier M, Pan L, Mitchell GA: Lipolysis and the integrated physiology of lipid energy metabolism. Mol Genet Metab 2008, 95(3):117–126.

12. American Diabetes Association: Standards of medical care in diabetes–2010. Diabetes Care 2010, 33(Suppl 1):S11–S61.
developed in collaboration with the American College of Emergency Physicians and Society for Cardiovascular Angiography and Interventions. *Catheter Cardiovasc Interv* 2013, 82(1):E1–E27.

14. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, Katus HA, Apple FS, Lindahl B, Morrow DA, Clemmensen FM, Johanson P, Hod H, Undén E, Warburton R, Bar JI, Bonow RO, Jint, Pinto F, Gibbons RJ, Fox KA, Atar D, Newby LK, Galvan M, Hamm CW, Uretsky BF, Steg PG. Third universal definition of myocardial infarction. *J Am Coll Cardiol* 2012, 60(16):1581–1598.

15. Hinareh L, Berglund M, Agewall S. Should oral glucose tolerance test be a routine examination after a myocardial infarction? *Int J Cardiol* 2004, 97(1):21–24.

16. Liu H, Zhou C, Yu J, Jiang Q, Hu D. Reduced kidney function in acute coronary syndrome patients with undiagnosed diabetes or pre-diabetes. *Nephrology (Carlton)* 2013, 18(4):263–268.

17. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. *Lancet* 2004, 364(9435):685–696.

18. Frayn KN. Plasma non-esterified fatty acids: why are we not measuring them routinely? *Ann Clin Biochem* 2005, 42(Pt 6):413–414.

19. Pitz S, Schamagl H, Tinan B, Steinhorst U, Wellnitz B, Boehm BO, Schaefer JR, Marz W. Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease. *J Clin Endocrinol Metab* 2006, 91(7):2542–2547.

20. Pitz S, Schamagl H, Tinan B, Wellnitz B, Steinhorst U, Boehm BO, Marz W. Elevated plasma free fatty acids predict sudden cardiac death: a 6.85-year follow-up of 3315 patients after coronary angiography. *Eur Heart J* 2007, 28(22):2763–2769.

21. Bays H, Mandarino L, Defronzas RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. *J Clin Endocrinol Metab* 2004, 89(2):463–478.

22. Opie LH. The metabolic vicious cycle in heart failure. *Lancet* 2004, 364(9447):1733–1734.

23. Jun JC, Drager LF, Najjar SS, Gottlieb SS, Brown CD, Smith PL, Schwartz AR, Polotsky VY. Effects of sleep apnea on nocturnal free fatty acids in subjects with heart failure. *Sleep* 2011, 34(9):1207–1213.

24. Stanley WC, Recchia FA, Lopachuk GD. Myocardial substrate metabolism in the normal and failing heart. *Physiol Rev* 2005, 85(3):1093–1129.

25. Oliver MF. Sudden cardiac death: the lost fatty acid hypothesis. *QJM* 2006, 99(10):701–709.

26. Roy WK, Kumar A, Ioshi P, Aasa J, Ahanger AM. Plasma free Fatty Acid concentrations as a marker for acute myocardial infarction. *J Clin Diagn Res* 2013, 7(11):2432–2434.

27. Jukema JW, Liem AH, Dunselman PH, van der Sloot JA, Lok DJ, Zwinderman AH. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-cholesterol. *Results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study*. *Curr Med Res Opin* 2005, 21(11):1865–1874.

28. Berghoavan SC, Van Tol A, Dalilina-Thie GM, Liem A, Dunsellman PH, Van der Bom JG, Jukema JW. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. *Curr Med Res Opin* 2007, 23(9):2235–2240.

29. de Nijt T, Sinderman A, de Graaf J. ApoB versus non-HDL-cholesterol. *Diagnosis and cardiovascular risk management*. *Crit Rev Clin Lab Sci* 2013, 50(6):163–171.

30. Ladue JS, Wroblewski F, Karmen A. Serum glutamic oxaloacetic transaminase activity in human acute transmural myocardial infarction. *Science* 1954, 120(3117):497–499.

31. Lothrus DM, Stevens SR, Armstrong PW, Granger CB, Mahaffey KW. Pattern of liver enzyme elevations in acute ST-elevation myocardial infarction. *Coron Artery Dis* 2012, 23(1):22–29.